Investments, Funding & Disinvestment

The updated platform now connects customers with companies such as Twin Health, Curai Health, Wheel, Berry Street, and Aaptiv.

MyGenius PRO adds to Bruker’s molecular diagnostics portfolio, which includes InGenius, BeGenius, and LiquidArray assays.

Exhibitors will present a wide range of medical technologies and products, including surgical equipment, diagnostic systems, and pharmaceutical solutions.

The agreement also includes potential clinical, regulatory, and commercial milestone payments that could raise the total value to USD7 billion,

Biogen now holds worldwide rights to the investigational therapy, felzartamab, which is currently undergoing Phase 3 clinical trials for several immune-mediated diseases.

AI Diagnostics developed its Ostium digital stethoscope and AI.TB software to support frontline healthcare providers, including nurses, pharmacists, and community health workers.

The therapy, known as NRTX-1001, uses pluripotent stem cells engineered to regulate brain activity and repair damaged neural networks.

Under the agreement, Stereotaxis will pay USD20 million upfront, with up to an additional USD25 million tied to milestone-based payments.

The company grew revenue by 10% to EUR 1.75 billion (USD1.91 billion) while substantially improving profitability and cash generation.

For Daiichi Sankyo, divesting this business allows the company to concentrate resources on its innovative medicines division, where it has emerged as a leader in antibody-drug conjugate (ADC) technology.